Table 2 Univariate and multivariate analyses of the demographic, clinical characteristics, and risk factors in CDC groups
Characteristics | CDC group (n = 33) | non-CDC group (n = 66) | Univariate Analysis | Multivariable logistic regression Analysis | ||
|---|---|---|---|---|---|---|
n(%)/mean ± SD | n(%)/mean ± SD | OR (95% CI) | P value | OR (95% CI) | P value | |
Male | 17 (68.0) | 31 (62.0) | 0.768 (0.278–2.121) | 0.610 |  |  |
Age (mean ± SD) | 62 ± 18.93 | 59.06 ± 10.54 | – | 0.660 |  |  |
Clinical features | ||||||
Hospital duration (days) (mean ± SD) | 61.28 ± 66.12 | 16.98 ± 11.48 | – | 0.003* | 1.137 (1.05–1.23) | 0.002* |
Fever (≥ 38 °C) | 9 (36.0) | 7 (14.0) |  |  |  |  |
Leukocyte count (109 /L) (mean ± SD) | 9.84 ± 5.32 | 8.75 ± 5.07 | – | 0.389 |  |  |
Serum albumin (g/L) (mean ± SD) | 31.12 ± 5.55 | 33.80 ± 10.53 | – | 0.238 |  |  |
Serum creatinine rise> 50%(μmol/L) | 2 (8.0) | 5 (10) | – | 0.779 |  |  |
Mortality | 3 (12.0) | 2 (4.0) | 3.273 (0.51–21.002) | 0.190 |  |  |
Classification of primary diagnosis | ||||||
Gastrointestinal | 18 (72.0) | 30 (60.0) | 1.714 (0.606–4.852) | 0.307 |  |  |
Respiratory | 15 (60.0) | 19 (38.0) | 2.447 (0.916–6.541) | 0.071 | 0.043 (0.002–0.969) | 0.048* |
Cardiovascular | 7 (28.0) | 18 (36.0) | 0.691 (0.243–1.969) | 0.488 |  |  |
Renal | 9 (36.0) | 15 (30.0) | 1.313 (0.475–3.626) | 0.600 |  |  |
Neurologic | 6 (24.0) | 3 (6.0) | 4.947 (1.121–21.838) | 0.024* |  |  |
Metabolic disorders | 12 (48.0) | 26 (52.0) | 0.852 (0.326–2.227) | 0.744 |  |  |
NO. of comorbidities | ||||||
1–2 | 13 (52.0) | 33 (66.0) | – | 0.139 | 36.509 (2.602–512.183) | 0.008* |
3–4 | 9 (36.0) | 17 (34.0) | ||||
≥5 | 3 (12.0) | 0 (0) | ||||
Treatments and procedures | ||||||
Surgical intervention | 10 (40.0) | 4 (8.0) | 7.667 (2.094–28.068) | 0.001* |  |  |
Enteral feeding | 16 (64.0) | 16 (32.0) | 3.778 (1.376–10.372) | 0.008* |  |  |
PPI use | 8 (32.0) | 25 (50.0) | 0.471 (0.172–1.288) | 0.139 |  |  |
Antibiotics use | 24 (96.0) | 41 (82.0) | 5.268 (0.628–44.178) | 0.093 |  |  |
Antiviral drugs | 2 (8.0) | 3 (6.0) | 1.362 (0.213–8.729) | 0.743 |  |  |
Antifungal agents | 7 (28.0) | 4 (8.0) | 4.472 (1.166–17.146) | 0.021* |  |  |
Cephalosporin | 9 (36.0) | 24 (48.0) | 0.609 (0.227–1.636) | 0.324 |  |  |
Fluoroquinolone | 5 (20.0) | 8 (16.0 | 1.313 (0.381–4.525) | 0.666 |  |  |
Carbapenem | 18 (70.0) | 21 (42.0) | 3.551 (1.258–10.027) | 0.014* |  |  |
Vancomycin | 12 (48.0) | 7 (14.0) | 5.67 (1.851–17.374) | 0.001* | 18.168 (1.036–318.503) | 0.047* |
Metronidazole | 2 (8.0) | 12 (24.0) | 0.275 (0.056–1.342) | 0.094 | 0.013 (0–0.512) | 0.021* |
NO. of antibiotics received | ||||||
0 | 1 (4.0) | 9 (18.0) | – | 0.076 |  |  |
1–2 | 16 (64.0) | 33 (66.0) | ||||
≥3 | 8 (32.0) | 8 (16.0) | ||||